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Abstract
Therapeutic inertia is a substantial obstacle to the initiation of insulin therapy in people with uncontrolled type 2 diabetes 
(T2D). This effect has in part been perpetuated by concerns over the impact of a burdensome regimen and the increased risk 
of hypoglycemia and body weight gain often associated with insulin use. An effective, yet simple, less burdensome regimen 
with a lower risk of body weight gain and hypoglycemia compared with an insulin-only regimen, may help to address these 
concerns more effectively. We review the available clinical and real-world data on IDegLira, a once-daily, injectable, fixed-
ratio combination of insulin degludec (degludec) and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, 
in people with T2D. Evidence from the comprehensive DUAL clinical trial program suggests an advantage of IDegLira over 
traditional insulin therapies in a number of clinical outcomes, including maintenance of glycemic control, achievement of gly-
cemic targets, reducing the risk of hypoglycemia, and body weight loss. These findings were demonstrated in participants with 
T2D irrespective of prior GLP-1RA and insulin use. Furthermore, the individual components of IDegLira have confirmed 
safety (degludec) or significant benefit in terms of improvement of cardiovascular risk (liraglutide). As an injectable therapy 
that is simple to titrate, IDegLira has the potential to optimize the ability to achieve relevant glycemic targets, and offers 
a suitable treatment option for people with T2D requiring insulin therapy who are at risk of hypoglycemia or weight gain.
Key Points 
People with type 2 diabetes (T2D) and healthcare profes-
sionals can be reluctant to start insulin therapy.
IDegLira is a medicine that combines insulin with a 
glucagon-like peptide-1 receptor agonist, that can help 
people with T2D improve their blood sugar and reduce 
their risk of weight gain and hypoglycemia.
IDegLira allows for simple dose adjustment with a once 
daily injection, which combined with clinical benefits, 
may make it a more attractive option for those reluctant 
to start insulin.
1 Introduction
Type 2 diabetes (T2D) is a chronic, progressive disease 
with an etiology involving insulin resistance and progres-
sive decline in β-cell function [1]. Current clinical practice 
guidelines recommend exercise and diet modification as the 
first-line therapy, alone or in combination with metformin. 
Treatment is intensified over time with the addition of fur-
ther oral antidiabetes drugs (OADs) and/or injectable thera-
pies, often in combination with each other [2, 3].
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-
1RAs) mimic naturally occurring GLP-1, a hormone secreted 
in response to food ingestion that enhances the release of 
endogenous insulin and suppresses endogenous glucagon 
secretion, both in a glucose-dependent manner. Both GLP-
1RA and basal insulin are recommended treatment options at 
many stages of T2D. These agents have complementary mech-
anisms of action, which, when used together, can offer several 
benefits to people with T2D [4, 5]. Basal insulin is effective at 
lowering glycated hemoglobin  (HbA1c) and fasting plasma glu-
cose (FPG) levels, but increases the risk of hypoglycemia and 
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body weight gain [4, 5]. Short-acting GLP-1RAs (exenatide, 
lixisenatide) lower postprandial glucose (PPG) when taken 
before a meal, whereas long-acting GLP-1RAs (dulaglutide, 
exenatide extended release, liraglutide, and semaglutide) lower 
both FPG and PPG; both act in a glucose-dependent man-
ner. GLP-1RAs slow gastric emptying and increase satiety; 
however, GLP-1RAs can cause gastrointestinal (GI) adverse 
events, notably nausea and vomiting, especially in the early 
weeks of therapy. GLP-1RAs are suitable adjuncts to basal 
insulin as they can mitigate body weight gain and lower the 
risk of hypoglycemia since their co-use reduces the insulin 
dose requirement [4, 5]. Therefore, the combination of these 
two therapies can be more effective yet better tolerated than 
basal insulin or GLP-1RA alone.
Co-formulations of oral therapies are well established, with 
many combinations of different drug classes currently avail-
able [6]. More recently, two injectable fixed-ratio combination 
(FRC) formulations of basal insulin and GLP-1RA have been 
approved [7]: IDegLira (first approved in the EU in 2014, and 
in the US in 2016) is a once-daily FRC of insulin degludec 
U100 (degludec) and the GLP-1RA liraglutide [8]; and IGlar-
Lixi (approved in the US in 2016, and in the EU in 2017) 
is a once-daily FRC of insulin glargine U100 (IGlar U100) 
and lixisenatide (a GLP-1RA). Both IDegLira and IGlarLixi 
demonstrated either non-inferiority or superiority in  HbA1c 
reduction compared with their basal insulin and GLP-1RA 
components in monotherapy, respectively, in the DUAL I [8, 
9] and LixiLan-O [10] trials.
The combination of an insulin and a GLP-1RA into one 
treatment simplifies therapy, halving the number of injections 
when compared with taking each component separately, and 
thereby reducing treatment burden [11]. Additionally, fewer 
GI adverse events are associated with FRCs of GLP-1RAs 
compared with the use of GLP-1RAs in free combination, as 
a result of a lower GLP-1RA starting dose and more gradual 
titration of the FRC, determined by the insulin component 
[12]. Furthermore, oral combination therapies have been 
shown to significantly improve treatment initiation and per-
sistence compared with usual care [13]; this may also be appli-
cable to injectable combination therapies. To support their use 
in clinical practice, clinicians need to be familiar with the ini-
tiation and titration of FRC products, and to identify suitable 
people who will benefit from this therapy [14].
This review focuses on the clinical evidence for one of the 
injectable FRCs, namely IDegLira, to explore its potential 
role in T2D therapy.
2  Unmet Clinical Need
Reaching and maintaining personalized glycemic targets 
has been shown to improve outcomes in people with dia-
betes by reducing micro- and macrovascular complications 
[15]. However, it is well established in clinical practice 
that people with diabetes often do not reach  HbA1c targets 
[16, 17] and that healthcare professionals (HCPs) can be 
reluctant to intensify therapy in a timely manner as recom-
mended by clinical practice guidelines [3, 18, 19]. This 
phenomenon has been referred to as therapeutic inertia 
[20].
Therapeutic inertia, also called clinical inertia, can lead 
to delays in initiating insulin therapy in people with T2D 
with elevated  HbA1c levels [21–23]. Although significant 
improvements in glycemic control have been observed when 
insulin therapy was initiated in individuals not achieving 
 HbA1c targets with OADs alone, most people still did not 
achieve an  HbA1c target of < 7.0% (< 53 mmol/mol), even if 
this was their target level [22–24].
A number of reasons have been proposed for therapeutic 
inertia, such as HCPs being concerned about the impact of 
burdensome regimens on the quality of life of people with 
T2D, or their fears of causing people with T2D to experi-
ence hypoglycemia and body weight gain. It is important 
to recognize that therapeutic inertia might be the result of 
shared decision making, as people with diabetes are likely 
to share these concerns and may be reluctant to intensify 
their treatment [20].
A simple, less burdensome injectable therapy with a 
lower risk of body weight gain and hypoglycemia compared 
with an insulin-only regimen, requiring only a single daily 
injection, has the potential to reduce such concerns on the 
part of both HCPs and people with diabetes, thereby opti-
mizing the ability to achieve relevant  HbA1c targets. Fur-
thermore, by combining drugs with complementary actions, 
an FRC has the potential to provide more durable glycemic 
control. A durable therapy is defined as one that helps peo-
ple with diabetes maintain glycemic control for longer and 
therefore require fewer intensification interventions com-
pared with other treatment options. As a result of the chronic 
nature of T2D, a durable therapy could play an important 
role in preventing therapeutic inertia and minimizing chronic 
exposure to hyperglycemia. Additionally, the need for fewer 
interventions may lead to people with T2D feeling more 
positive about their disease management [25].
3  Pharmacokinetic and Pharmacodynamic 
Properties of IDegLira and Its Constituents
A one-unit dose (used in the US prescribing information) 
or dose step (used in the European Summary of Product 
Characteristics) of IDegLira comprises 1 unit of degludec 
and 0.036 mg of liraglutide. IDegLira is administered once-
daily by subcutaneous injection, at any time of the day, but 
preferably at the same time each day [7].
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3.1  Pharmacokinetic and Pharmacodynamic 
Properties of Degludec
Degludec is a long-acting, once-daily basal insulin. When 
injected, degludec forms a subcutaneous depot of multi-
hexamers, from which monomers slowly and continuously 
dissociate [26]. It has a half-life of more than 25 h (com-
pared with approximately 12 h for IGlar U100 and 5–7 h 
for insulin detemir), and provides a consistent and stable 
blood glucose-lowering profile over each 24-h dosing inter-
val [26–28], as well as relatively low day-to-day variability 
in the pharmacodynamic profile compared with other basal 
insulins [29, 30]. The within-day variability in the glucose-
lowering effect of degludec has also been found to be lower 
by 40% and 37% compared with IGlar U100 and U300, 
respectively [30]. This reduction in glucose-lowering vari-
ability is likely to be associated with the significantly lower 
risk of overall hypoglycemia compared with IGlar U100, 
as demonstrated in the SWITCH [31, 32], DEVOTE [33], 
and BEGIN [34] trials. By contrast, morning administration 
of IGlar U300 0.4 units/kg/day in individuals with type 1 
diabetes (T1D) provides less fluctuating 24-h pharmacody-
namics and more even pharmacokinetic profiles compared 
with degludec 100 units/mL [35].
3.2  Pharmacokinetic and Pharmacodynamic 
Properties of Liraglutide
Liraglutide is a once-daily, injectable GLP-1RA, sharing 
97% sequence homology with human GLP-1 [36]. It is 
metabolized by dipeptidyl peptidase-4 (DPP-4) and neutral 
endopeptidase at a much slower rate than naturally occur-
ring GLP-1 [37]. Absorption of liraglutide is slow (reach-
ing maximum concentration 8–12 h after dosing) and the 
half-life is 13 h, hence its suitability for once-daily dosing 
[36]. Liraglutide restores the β-cell insulin response, which 
is impaired in people with T2D, to levels similar to healthy 
individuals [38].
3.3  Pharmacokinetic and Pharmacodynamic 
Properties of IDegLira
The discrete pharmacokinetic properties of degludec and 
liraglutide are preserved when administered as the IDegLira 
co-formulation, with equivalence being demonstrated com-
pared with both degludec and liraglutide monotherapy [39].
The maximum daily dose of IDegLira is 50 units/dose 
steps [7], as this delivers the maximum licenced liraglutide 
dose for diabetes of 1.8 mg [36]. While there may be con-
cern that the dose of degludec is capped at 50 units in IDe-
gLira, the insulin requirement of people with T2D treated 
with IDegLira is greatly reduced as a result of the insulin-
sparing effect of liraglutide [40, 41].
4  Degludec and Liraglutide Clinical Trials
4.1  Degludec Clinical Trials
BEGIN® was a phase III clinical trial program that inves-
tigated the efficacy and safety of degludec in more than 
3000 people with T1D or T2D. It demonstrated degludec 
to be associated with a lower risk of hypoglycemia than 
IGlar U100 at the same  HbA1c level, and to offer more dos-
ing flexibility [42–46]. Both insulin-naïve people [43–46] 
and those who had previously been treated with insulin 
[42, 43] were included. As these trials had a treat-to-target 
design, people treated with degludec achieved non-inferior 
reductions in  HbA1c compared with those treated with 
IGlar U100.
The total end-of-trial daily insulin dose was either simi-
lar in each treatment group [42, 43, 46] or statistically 
significantly lower (11–20%) in participants receiving 
degludec compared with IGlar U100 in people with T2D 
[44, 45].
A preplanned meta-analysis of seven trials of deglu-
dec compared with IGlar U100 demonstrated that people 
with T2D treated with degludec experienced significantly 
lower rates of overall and nocturnal confirmed hypoglyce-
mic episodes {estimated rate ratios (ERRs) of 0.83 (95% 
confidence intervals [CIs] 0.74; 0.94) and 0.68 (95% CI 
0.57; 0.82), respectively} [34]. The SWITCH 2 crossover 
trial confirmed that participants with T2D treated with 
degludec had significantly lower rates of overall and noc-
turnal confirmed hypoglycemia than people treated with 
IGlar U100 (ERR of 0.70 [95% CI 0.61; 0.80] and 0.58 
[95% CI 0.46; 0.74], respectively) [31]. The proportion 
of participants experiencing at least one severe episode 
of hypoglycemia was also lower with degludec (1.6%) 
compared with IGlar U100 (2.4%), but the difference did 
not reach significance [31]. SWITCH 2 demonstrated the 
safety of degludec in a high-risk population more reflec-
tive of everyday clinical practice as it enrolled participants 
who were at higher risk for hypoglycemia at baseline com-
pared with the BEGIN trials, which had excluded partici-
pants with recurrent severe hypoglycemia or hypoglycemia 
unawareness.
4.2  Liraglutide Clinical Trials
The efficacy and safety of liraglutide either as monother-
apy or in combination with OADs was investigated in more 
than 4000 people with T2D in the LEAD clinical trial pro-
gram [47, 48]. LEAD demonstrated that the administra-
tion of liraglutide once-daily led to significantly superior 
improvements in  HbA1c compared with a variety of OAD 
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comparators, with a low rate of hypoglycemia (lower than 
sulfonylureas and IGlar U100, but higher than placebo 
and rosiglitazone) and relative reductions in body weight 
compared with most comparators [49–54]. However, treat-
ment with liraglutide and other GLP-1RAs resulted in an 
increased incidence of GI adverse events, although these 
tended to be transient, decreasing over time [49–55].
5  Efficacy of Basal Insulin and GLP‑1RA 
in Free Combination
The complementary effects of free combinations of basal 
insulin and GLP-1RA therapy have been recognized for 
several years [56]. As an example, the BEGIN: ADD 
TO GLP-1 study investigated the efficacy and safety of 
administering degludec, compared with placebo, to people 
with T2D who had not achieved an  HbA1c target of < 7.0% 
(< 53  mmol/mol) with metformin and maximum-dose 
liraglutide (1.8 mg). After 26  weeks, 78% of partici-
pants receiving degludec had achieved  HbA1c < 7.0% 
(< 53  mmol/mol) compared with 36% of participants 
receiving placebo [57]. Another study investigated the 
effect of adding the basal insulin detemir to liraglutide 
and metformin in people with T2D with  HbA1c ≥ 7.0% 
(≥ 53 mmol/mol), and reported that 43% of participants 
achieved an  HbA1c target of < 7.0% (53 mmol/mol) com-
pared with 17% of participants receiving placebo [58].
A 26-week, double-blind, parallel-group, placebo-con-
trolled study investigated the effect of adding liraglutide to 
a pre-existing basal insulin analogue ± metformin in adults 
with inadequately controlled T2D  (HbA1c 7.0–10.0% 
[53–86 mmol/mol]) [59]. After 26 weeks, 59% and 43% 
of participants achieved  HbA1c < 7.0% (53 mmol/mol) 
or ≤ 6.5% (≤ 48 mmol/mol) with liraglutide, respectively, 
compared with 14% and 4% of participants receiving pla-
cebo, respectively. Liraglutide also resulted in significantly 
improved body weight and systolic blood pressure com-
pared with placebo [59].
A meta-analysis of 11 randomized controlled trials 
comparing free or fixed combinations of a GLP-1RA plus 
basal insulin with uptitration of basal insulin in people 
with T2D reported that the combination therapy led to 
a mean  HbA1c decrease significantly greater than insu-
lin uptitration (− 0.5% [− 6 mmol/mol], 95% CI − 0.66; 
− 0.40, p < 0.001); more individuals at the  HbA1c target 
of < 7.0% (relative risk [RR] 1.69, 95% CI 1.42; 2.00, 
p < 0.001); similar hypoglycemic events (RR 0.97, 95% 
CI 0.84; 1.12, p = 0.114); and reduction in body weight 
(− 1.9 kg, 95% CI − 2.3; − 1.4, p < 0.001). Results were 
consistent in both the free and fixed combination sub-
groups [60].
6  IDegLira Clinical Trials
The phase III, DUAL clinical trial program has demon-
strated the efficacy and safety of IDegLira in participants 
with T2D irrespective of prior GLP-1RA and insulin use 
(Table 1). The primary endpoint for the DUAL I–VII and 
IX trials was change in  HbA1c from baseline to end of trial 
(EOT) (Fig. 1) [8, 40, 41, 61–65]. The key clinical findings 
from the DUAL program are summarized in Panel 1.
Panel 1: Key Clinical Learnings from the DUAL Program
• IDegLira provides reductions in  HbA1c to all patient groups with 
T2D regardless of their prior treatment (DUAL I–VII and IX)
• Despite this level of glucose-lowering efficacy, people randomized 
to IDegLira experienced fewer hypoglycemic episodes compared 
with those treated with basal or basal–bolus insulin therapy (DUAL 
I, II, V, VII, and IX)
• On average, people transferring from basal insulin to IDegLira 
experienced beneficial body weight reduction or stabilization, 
compared with people treated with continued basal or basal–bolus 
therapy (DUAL II, V and VII)
• IDegLira is associated with a lower incidence of GI adverse events 
compared with liraglutide or exenatide (DUAL I extension and 
DUAL III)
• IDegLira is an efficacious treatment option for people who do not 
achieve sufficient glycemic control with regimens containing sulfo-
nylureas with or without metformin or basal insulin with or without 
metformin (DUAL IV, V and VII)
• Insulin-naïve people with T2D experienced greater durability of 
glycemic control when treated with IDegLira compared with IGlar 
U100 (DUAL VIII)
• IDegLira has a simple intensification regimen for people with 
T2D not reaching their glycemic targets on injectable therapy, as it 
enables intensification without additional daily injections (DUAL 
II, III, V, and VII)
• People switching to using IDegLira instead of adding bolus insulin 
to a basal insulin-based regimen can avoid the inconvenience of 
multiple daily insulin injections and reduce their total daily insulin 
dose in addition to benefiting from reductions in body weight and 
 HbA1c (DUAL VII)
HbA1c, glycated hemoglobin, GI gastrointestinal, GLP-1RA glucagon-
like peptide-1 receptor agonists, IDegLira insulin degludec/liraglu-
tide, IGlar insulin glargine, T2D type 2 diabetes
6.1  Insulin‑Naïve People Receiving Antidiabetes 
Drugs (OADs)
Five trials investigated the efficacy and safety of IDegLira as 
an add-on to OADs, in people who were insulin-naïve with 
inadequate glycemic control (Table 1).
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6.1.1  DUAL I: IDegLira Compared with Both Degludec 
and Liraglutide
DUAL I was a 26-week, randomized, open-label, paral-
lel-group trial that compared the efficacy and safety of 
IDegLira with its components, degludec and liraglutide, 
in combination with metformin with or without pioglita-
zone (Table 1). IDegLira was found to be non-inferior to 
degludec and superior to liraglutide in reduction in  HbA1c 
from baseline to EOT (Fig. 1a). Participants treated with 
IDegLira experienced fewer episodes of hypoglycemia, 
body weight loss compared with body weight gain, and 
a lower insulin dose (Fig. 1b–d), but higher rates of GI 
adverse events when compared with participants treated 
with degludec (Table 2). Participants treated with IDe-
gLira experienced more episodes of hypoglycemia and 
a reduced effect on weight loss (Fig. 1b, c), but with a 
lower rate of GI adverse events when compared with par-
ticipants treated with liraglutide (Table 2) [8].
6.1.2  DUAL IV: IDegLira Compared with Placebo
DUAL IV was a 26-week, randomized, double-blind, par-
allel-group trial that assessed the efficacy and safety of 
IDegLira as an add-on to sulfonylurea therapy (Table 1). 
Mean reduction of  HbA1c from baseline was superior 
for participants who received IDegLira compared with 
placebo (Fig. 1a). The rate of confirmed hypoglycemia 
was higher with IDegLira than with placebo and the 
two events of severe hypoglycemia reported in the trial 
both occurred in the IDegLira treatment group (n = 289) 
(Fig. 1b). The rate of hypoglycemia observed with IDeg-
Lira in DUAL IV was higher than that observed in other 
trials in the DUAL program and may be attributed to the 
effect of sulfonylurea therapy, which is associated with an 
increased risk of hypoglycemia (and weight gain), espe-
cially when combined with insulin therapy. There was no 
significant difference in the rates of nocturnal hypogly-
cemia between the treatment groups. Participants treated 
with IDegLira experienced a body weight gain compared 
with a body weight loss with placebo (Fig. 1c) [63].
6.1.3  DUAL VI: IDegLira Once‑Weekly Compared 
with Twice‑Weekly Titration
DUAL VI was a 32-week, randomized, open-label, parallel-
group trial that assessed the efficacy and safety of IDeg-
Lira as an add-on to existing OAD therapy when titrated 
using a pragmatic once-weekly algorithm, compared with 
twice-weekly titration (Table 1), as recommended in cur-
rent prescribing information [7, 66]. Mean reduction in 
 HbA1c in the once-weekly titration group was non-inferior 
to twice-weekly titration (Fig. 1a). Participants in both the 
once- and twice-weekly titration arms experienced low rates 
of hypoglycemia (Fig. 1b) and were receiving the same dose 
of IDegLira at EOT (Fig. 1d). Participants who titrated IDe-
gLira twice weekly achieved a significantly greater reduction 
in body weight compared with those who titrated IDegLira 
once weekly (Fig. 1c) [64].
6.1.4  DUAL VIII: IDegLira Compared with IGlar U100
DUAL VIII was a 104-week, open-label durability trial, 
comprising an initial 26 weeks where participants were 
titrated with either IDegLira or IGlar U100 to the  HbA1c 
target of < 7.0% (53 mmol/mol), followed by 78 weeks of 
monitoring (Table 1). The primary endpoint was time from 
randomization to inadequate glycemic control and need for 
treatment intensification, defined as  HbA1c ≥ 7.0% (53 mmol/
mol) at two consecutive visits from week 26 (including week 
26 if  HbA1c was ≥ 7.0% [53 mmol/mol] at week 12) up to 
104 weeks. Participants treated with IDegLira had a longer 
time to ‘need for treatment intensification’ (median > 2 years) 
compared with IGlar U100 (median approximately 1 year; 
p < 0.0001 accounting for baseline  HbA1c group and back-
ground sulfonylurea use as baseline strata). Furthermore, 
63% of participants treated with IDegLira did not require 
treatment intensification by week 104 compared with 34% of 
participants treated with IGlar U100. In addition to improved 
durability, participants in the IDegLira group also had a 
lower insulin dose (37 units compared with 52 units; esti-
mated treatment difference [ETD] − 14.9; 95% CI − 17.4; 
− 12.5; p < 0.0001), less body weight gain (1.7 compared 
with 3.4 kg; ETD − 1.70; 95% CI − 2.47; − 0.93; p < 0.0001), 
and experienced a lower incidence of hypoglycemia (0.38 
compared with 0.86 events per PYE; ERR 0.44; 95% CI 0.33; 
0.60; p < 0.0001) than participants in the IGlar U100 group, 
had treatment intensification not been needed. No new safety 
signals were observed over the 2-year trial period [67].
6.1.5  DUAL IX: IDegLira Compared with IGlar U100
This 26-week, open-label trial aimed to investigate the 
efficacy and safety of IDegLira as an add-on to a sodium-
glucose transport protein 2 inhibitor (Table 1). Participants 
treated with IDegLira achieved a superior reduction in mean 
 HbA1c from baseline to EOT compared with IGlar U100 
(Fig. 1a). Participants in the IDegLira treatment arm expe-
rienced significantly lower rates of hypoglycemia and less 
body weight gain compared with IGlar U100 (Fig. 1b, c). At 
the end of the study, participants in the IDegLira arm were 
receiving a significantly lower mean daily insulin dose than 
participants treated with IGlar U100 (Fig. 1d) [65].









IILAUDIIILAUDILAUD DUAL VIIDUAL VDUAL IV DUAL VI DUAL IX 
Add to OAD(s) Basal insulin switchGLP-1RAswitch
∆ HbA1c (%)
N 833 413 414 289 146 210 210 210 210 292 146 199 199 278 279 252 254
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IDegLira Liraglutide (DUAL I)/GLP-1RA (DUAL III)
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IGlar U100 (DUAL V and IX) 
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6.2  Insulin‑Naïve People Receiving GLP‑1RAs 
in Combination with OADs: IDegLira Compared 
with GLP‑1RA
The aim of DUAL III, a 26-week, randomized, open-label 
trial, was to investigate the efficacy of IDegLira in control-
ling glycemia in adults whose T2D was inadequately con-
trolled on GLP-1RA and OAD therapy (Table 1). Compared 
with unchanged GLP-1RA therapy, IDegLira was associated 
with a superior reduction in  HbA1c, a higher rate of hypogly-
cemia and a mean body weight gain compared with a mean 
body weight loss (Fig. 1a–c). However, participants treated 
with IDegLira had a lower rate of GI adverse events than 
those treated with unchanged GLP-1RA therapy (Table 2) 
[62].
6.3  People Receiving Basal Insulin and OADs
Three trials investigated the efficacy of IDegLira in peo-
ple switching from a basal insulin regimen (20–40 units or 
20–50 units) to IDegLira, compared with continuation with 
a basal insulin regimen, in combination with metformin, or 
initiation of a basal–bolus regimen [40, 41, 61].
6.3.1  DUAL II: IDegLira Compared with Degludec
DUAL II was a 26-week, randomized, parallel, double-
blind, treat-to-target trial comparing the efficacy and safety 
of IDegLira with the basal insulin degludec (maximum 50 
units), both in combination with metformin (Table 1). All 
pretrial glucose-lowering drugs were discontinued, except 
metformin. Participants treated with IDegLira experienced 
a superior reduction in  HbA1c compared with those treated 
with degludec (Fig. 1a). Furthermore, participants treated 
with IDegLira experienced a similar rate of confirmed hypo-
glycemia compared with degludec (Fig. 1b), and there was 
one severe hypoglycemic event in DUAL II, in a participant 
Fig. 1  Key findings from the DUAL program a change in  HbA1c at 
EOT; b rates of hypoglycemia; c change in body weight at EOT; and 
d insulin dose at EOT [8, 40, 41, 61–65]. *Statistically significant 
for non-inferiority. **Statistically significant for superiority; deglu-
dec was capped at 50 units in the DUAL II trial. DUAL VIII data 
have been excluded as a result of the 104-week durability trial design, 
which is not directly comparable with the other DUAL studies. 1WT 
once-weekly titration, 2WT twice-weekly titration, CI confidence 
interval, EOT end of trial, ERR estimated rate ratio, ETD estimated 
treatment difference, GLP-1RA glucagon-like peptide-1 receptor ago-
nist, HbA1c glycated hemoglobin, IAsp insulin aspart, IDegLira insu-
lin degludec/liraglutide, IGlar insulin glargine, NR not reported, OAD 
oral antidiabetic therapy, PYE participant-year exposure, U units of 
insulin
◂
Table 2  Gastrointestinal adverse events in participants in the DUAL clinical trial program
1WT once-weekly titration, 2WT twice-weekly titration, GLP-1RA glucagon-like peptide-1 receptor agonist, IAsp insulin aspart, IDegLira insu-
lin degludec/liraglutide, IGlar insulin glargine, NR not reported, OAD oral antidiabetic therapy, PYE participant-year exposure
Previous treatment 
regimen
DUAL trial Treatment group Nausea (events per 
100 PYE)
Diarrhea (events per 
100 PYE)
Vomiting 
(events per 100 
PYE)
OAD(s) DUAL I IDegLira 20.9 23.5 10.1
Degludec 8.8 10.3 3.1
Liraglutide 54.3 39.8 23.6
DUAL IV IDegLira 11.3 10.5 5.3
Placebo 8.0 12.9 6.4
DUAL VI IDegLira 1WT 13.1 4.9 3.3
IDegLira 2WT 15.7 5.5 3.1
DUAL VIII IDegLira 4.9 6.4 2.9
IGlar U100 1.4 2.2 1.7
DUAL IX IDegLira 21.3 12.6 4.8
IGlar U100 1.9 7.6 3.8
GLP-1RA DUAL III IDegLira 7.8 12.8 2.8
Pre-trial liraglutide or exenatide 10.6 13.7 9.1
Basal insulin DUAL II IDegLira 21.8 22.8 9.8
Degludec 7.8 8.9 NR
DUAL V IDegLira 26.2 17.7 17.0
IGlar U100 2.2 7.4 3.7
DUAL VII IDegLira 30.7 19.9 10.0
IGlar U100 + IAsp (≤ 4 times) 3.4 14.2 5.9
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receiving IDegLira. The rate of nocturnal hypoglycemia 
observed in participants treated with IDegLira did not differ 
between groups, nor did the total EOT insulin dose between 
the degludec monotherapy and IDegLira treatment arms in 
this dose-capped study (Fig. 1d). IDegLira was associated 
with an average decrease in body weight compared with no 
change in body weight with degludec (Fig. 1c) [61].
6.3.2  DUAL V: IDegLira Compared with IGlar U100
DUAL V was a 26-week, randomized, treat-to-target trial 
that compared the efficacy of IDegLira and IGlar U100 in 
individuals who had insufficient glycemic control while tak-
ing metformin and IGlar U100 (20–50 U) (Table 1). Par-
ticipants randomized to IGlar U100 started the trial on their 
pretrial dose and uptitrated their treatment over the course 
of the trial, as required. Participants treated with IDegLira 
experienced a superior reduction in mean  HbA1c compared 
with IGlar U100 uptitration (Fig. 1a), while participants 
treated with IDegLira had significantly fewer episodes of 
confirmed hypoglycemia than those treated with the compar-
ator (Fig. 1b). Only one participant who was receiving IGlar 
U100 experienced severe hypoglycemia in DUAL V. Partici-
pants treated with IDegLira were statistically significantly at 
less risk of experiencing confirmed nocturnal hypoglycemia 
than people treated with IGlar U100. There was a significant 
reduction in the total daily insulin dose, and participants in 
the IDegLira group experienced body weight loss compared 
with those in the IGlar U100 group, who experienced body 
weight gain (Fig. 1c, d) [41].
6.3.3  DUAL VII: IDegLira Compared with Multiple Daily 
Insulin Injections (MDIs)
DUAL VII was a 26-week, open-label, two-arm parallel, 
randomized, treat-to-target trial. It investigated the efficacy 
and safety of IDegLira compared with multiple daily insulin 
injections (MDIs; basal insulin IGlar U100 combined with 
bolus insulin aspart [IAsp] ≤ 4 times daily), in people with 
T2D not reaching their glycemic targets with basal insu-
lin (Table 1). Participants experienced similar reductions 
in  HbA1c in both the IGlar U100 and IAsp and IDegLira 
treatment arms (Fig. 1a). Participants treated with IDegLira 
had significantly fewer episodes of confirmed hypoglyce-
mia than those treated with the comparator (Fig. 1b). Fur-
thermore, participants treated with IDegLira had fewer epi-
sodes of severe hypoglycemia and nocturnal hypoglycemia 
compared with IGlar U100 and IAsp. Participants treated 
with IDegLira were receiving a significantly lower insulin 
dose at EOT than those treated with IGlar U100 and IAsp 
(Fig. 1c). IDegLira was also associated with body weight 
loss compared with body weight gain in the IGlar U100 and 
IAsp arm (Fig. 1d) [40].
6.4  People Not Tolerating MDI Regimens
While the efficacy of IDegLira has been compared with 
MDIs in the DUAL VII trial, the efficacy of switching from 
an MDI regimen to an IDegLira regimen has not yet been 
investigated in a clinical trial setting. However, real-world 
data have demonstrated the effectiveness of IDegLira in indi-
viduals who had switched from MDIs.
The EXTRA study, a real-world retrospective 
chart review, collected data on 173 people receiving 
MDIs ± OADs who switched to treatment with IDeg-
Lira [68]. Over 6 months of treatment, these people had a 
mean 0.7% (8 mmol/mol) reduction in  HbA1c (from 8.3% 
[67 mmol/mol] to 7.6% [60 mmol/mol]; p < 0.0001), which 
was accompanied by a 31% reduction in daily insulin dose 
(from 65 units to 45 units; p < 0.0001), and a 2.4-kg decrease 
in body weight (from a baseline of 102.3 kg; p < 0.0001) 
[68]. This observational study suggests that people switching 
to IDegLira from an MDI regimen can avoid the inconven-
ience of multiple daily injections, reducing total daily insulin 
dose in addition to experiencing beneficial changes in body 
weight and  HbA1c.
6.5  Cardiovascular (CV) Safety
US FDA guidelines [69] require an assessment of cardio-
vascular (CV) safety for all new diabetes drugs. Although a 
CV outcome trial (CVOT) has not been conducted in peo-
ple treated with IDegLira, CVOTs have been conducted 
on the individual components: degludec (DEVOTE [33]) 
and liraglutide (LEADER [70]). DEVOTE demonstrated 
that degludec was non-inferior to glargine with respect to 
the incidence of major CV events (MACE) in participants 
with T2D at high risk for CV events (n = 7637) [33]. A post 
hoc analysis of participants in DEVOTE, which compared 
outcomes between participants concomitantly treated with 
liraglutide with those who had no liraglutide use, found 
that participants treated with degludec or IGlar U100 with 
liraglutide had significantly fewer MACE compared with 
participants in the degludec/IGlar U100 without liraglutide 
group (hazard ratio [HR] 0.62, 95% CI 0.41; 0.92; p = 0.02 
[71]). This observation suggested that liraglutide might have 
CV benefits for people treating their T2D with basal insulin.
The LEADER trial demonstrated that participants with 
T2D at high risk for CV disease (n = 9340) receiving sub-
cutaneous injections of liraglutide 1.8 mg had a lower risk 
of CV events and death from any cause than those receiving 
placebo [70]. Results of a post hoc analysis of LEADER 
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that compared participants receiving no insulin treatment, 
basal-only insulin, or other insulin in addition to liraglu-
tide suggest that the relative cardioprotection of liraglutide 
(compared with placebo) is preserved, at least in participants 
also using basal insulin; however, it should be noted that 
the study was not designed and powered for these post hoc 
analyses [72].
In addition to the DEVOTE and LEADER trials, further 
information on the effect of IDegLira on known CV risk fac-
tors beyond blood glucose has been provided by post hoc anal-
yses of the DUAL II, V, and VII studies [73]. These analyses 
found that participants treated with IDegLira experienced a 
greater decrease in mean systolic blood pressure, consistently 
lower or equal levels of low-density lipoprotein (LDL), and a 
small but statistically significant increase in heart rate, com-
pared with the basal insulin comparators. In the DUAL II 
trial, no differences between treatments were seen for high-
sensitivity C-reactive protein, whereas apolipoprotein B and 
brain natriuretic peptide were significantly lower with IDeg-
Lira compared with degludec after 26 weeks [73].
Taken together, these data indicate that IDegLira is asso-
ciated with a general improvement in CV risk markers com-
pared with basal insulin or basal–bolus therapy [73].
Key clinical learning The components of IDegLira have 
confirmed non-inferiority (degludec compared with IGlar 
U100) and superiority (liraglutide compared with pla-
cebo), in terms of incidence of MACE in their respective 
CVOTs [33, 70]. Additionally, there is evidence of a general 
improvement in CV risk markers in people treated with IDe-
gLira compared with participants treated with basal insulin 
[73].
7  Cost‑Effectiveness Analysis of IDegLira
The cost effectiveness of treatment interventions is a key 
consideration when choosing therapies for people with 
T2D. Direct comparison of the acquisition costs of dif-
ferent therapies is insufficient to inform healthcare payer 
decision making as there are multiple factors to consider 
aside from achieving glycemic control, including the like-
lihood and burden of adverse events such as hypoglycemia 
and body weight gain, quality of life, and, importantly, the 
prognosis for diabetes-related micro- and macrovascular 
complications [74–76].
Short- and long-term cost-effectiveness analyses of IDe-
gLira in comparison with uptitration of IGlar U100 and 
basal–bolus therapy of IGlar U100 and IAsp, have been 
conducted [74–79]. Based on clinical trial data from both 
the US and the UK, IDegLira has been shown to provide a 
cost-effective treatment option in people with uncontrolled 
T2D (Table 3) [74–79]. In the analyses where IDegLira 
was associated with increased costs, incremental cost-
effectiveness ratios remained well below the US value-
based price benchmark of $100,000–$150,000 per quality-
adjusted life-year (QALY) gained suggested by the Institute 
for Clinical and Economic Review, or the commonly 
accepted willingness-to-pay threshold of £20,000–£30,000/
QALY in the UK (Table 3). The short-term cost of control 
analyses (cost per person achieving treatment targets) have 
reported lower or equivalent annual costs of control with 
IDegLira in comparison with basal–bolus therapy or basal 
insulin uptitration, both for glycemic targets  (HbA1c ≤ 6.5% 
[≤ 48 mmol/mol] or < 7.0% [< 53 mmol/mol]) singularly 
and for composite endpoints without hypoglycemia and/or 
Table 3  Treatment costs associated with IDegLira compared with basal or basal–bolus insulin regimens
IAsp insulin aspart, IDegLira insulin degludec/liraglutide, IGlar insulin glargine, QALY quality-adjusted life-year, ICER incremental cost-effec-
tiveness ratio, SMBG self-measured blood glucose
a Total annual treatment cost, unless stated otherwise
b Values derived from sensitivity analysis in which needle and SMBG costs were excluded
Treatments Annual per participant 
difference in costs ($)a
Total cost savings over a 
participant’s lifetime
ICER (life expectancy) 
per life-year gained
ICER (quality-adjusted life 
expectancy) per QALY 
gained
IDegLira compared with uptitrated IGlar U100
 Davies et al. 2016 [78] – £1441 £7130 £6090
 Hunt et al. 2017 [74] – $16,970 $96,039 $63,678
 Hunt et al. 2017 [75] $3546 – – –
IDegLira compared with IGlar U100 + IAsp
 Davis et al. 2016 [78] – £1698 IDegLira dominant IDegLira dominant
 Dempsey et al. 2018 [77] – $3571 IDegLira dominant IDegLira dominant [$4050b]
 Dempsey et al. 2018 [77] −$743.44 [+ $267.97a] – – IDegLira dominant [$2211b]
 Drummond et al. 2018 [76] +£303 [+ £794a] – – £5924 [£15,505b]
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body weight gain [75, 79]. For example, in an analysis of 
the full DUAL V trial population, the annual cost per par-
ticipant achieving a target of  HbA1c ≤ 6.5% (48 mmol/mol) 
was lower with IDegLira than with continued uptitration 
of IGlar U100 ($18,556 compared with $21,862); however, 
the cost per participant achieving  HbA1c < 7.0% (53 mmol/
mol) was similar in the two arms ($14,358 compared with 
$14,327) [75].
8  Use of IDegLira in Clinical Practice
8.1  Initiation
IDegLira is given as a once-daily subcutaneous injection, 
which can be administered at any time of the day, but prefer-
ably around the same time each day [7]. People not reach-
ing glycemic targets while receiving OADs, GLP-1RAs, 
and basal insulin can successfully switch to IDegLira, as 
described in the DUAL trials [8, 40, 41, 61–63, 65] (Fig. 1).
The people who may benefit from a GLP-1RA and 
basal insulin FRC therapy based on our expert opinion are 
described in Panel 2, while information on how best to initi-
ate IDegLira is provided in Fig. 2.
Panel 2: Clinical Profiles for People with T2D and Consideration for 
use of GLP-1RA/Basal Insulin FRC Therapy
We recommend GLP-1RA/basal insulin FRCs such as IDegLira be 
considered as a first injectable therapy for people with T2D
GLP-1RA/basal insulin FRCs should also be considered as an 
alternative for people with T2D not reaching their glycemic targets 
when treated with:
• GLP-1RA monotherapy
• Basal insulin—in people who might otherwise require intensifica-
tion with MDIs
• Twice-daily basal insulin—in people with recurrent hypoglycaemia
•  MDIsa
a The use of IDegLira in people with T2D receiving MDIs is not 
approved and has not been investigated in a clinical trial
HbA1c, glycated hemoglobin, FRC fixed ratio combination, GLP-1RA 
glucagon-like peptide-1 receptor agonists, IDegLira insulin deglu-
dec/liraglutide, MDIs multiple daily insulin injections, T2D type 2 
diabetes
8.1.1  Addition of IDegLira for People Not Reaching Targets 
While Taking OADs
IDegLira is licensed in Europe and the US as an addition 
to OAD for people not reaching glycemic targets [7, 66]. 
No Yes Yes No
Determine the previous regimen
OADs
(insulin naïve)








Is the patient currently receiving
DPP-4is, SUs or pioglitazone?
Discontinue GLP-1RA therapy
Is the patient also receiving OADs?
Discontinue basal insulin
Is the patient also receiving OADs?
Is the patient currently receiving




















Fig. 2  IDegLira initiation algorithm to provide guidance for physi-
cians based on prior therapy of individuals with T2D. DPP-4i dipep-
tidyl peptidase 4 inhibitor, GLP-1RA glucagon-like peptide-1 receptor 
agonist, IDegLira insulin degludec/liraglutide, OAD oral antidiabetic 
drug, SU sulfonylurea
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In these people, IDegLira should be initiated at 10 units/
dose steps.
Most OADs can be continued when initiating IDegLira 
without modification. DPP-4 inhibitors are not contrain-
dicated in people initiating IDegLira [7, 66]; however, 
the combination of DPP-4 inhibitors with GLP-1RAs has 
no observed clinical benefit [80] and therefore we recom-
mend discontinuation of DPP-4 inhibitors when initiating 
IDegLira.
People can continue treatment with pioglitazone when 
initiating IDegLira, but it is important to note that cases 
of cardiac failure have been reported when pioglitazone 
has been combined with insulin products, particularly in 
people with CV risk factors. Therefore, if pioglitazone is 
continued when IDegLira is initiated, these individuals 
should be closely monitored for symptoms of heart fail-
ure, body weight gain, and edema. If any of these symp-
toms or signs occur, pioglitazone should be discontinued 
[7].
Sulfonylureas can be continued in individuals when 
IDegLira is initiated, as demonstrated by the DUAL IV 
trial that assessed the efficacy and safety of IDegLira in 
people with T2D as an add-on to pretrial sulfonylurea 
(with or without metformin; Table 1 [63]); however, a 
reduction in dose and a plan to discontinue should be con-
sidered for those close to their glycemic target to reduce 
the risk of hypoglycemia and body weight gain associ-
ated with combining basal insulin or GLP-1RAs with 
sulfonylureas [7, 36]. A post hoc analysis of the DUAL 
II trial grouped participants by pretrial sulfonylurea use 
to investigate glycemic control in those who switched to 
IDegLira. This analysis demonstrated that participants 
who discontinued sulfonylureas and initiated IDegLira 
experienced no loss of glycemic control in the weeks after 
switching to IDegLira, and reached good glycemic control 
by week 26 regardless of pretrial sulfonylurea use [81]. 
While the rates of hypoglycemia were higher in people 
treated with IDegLira and sulfonylureas concurrently 
compared with placebo, the rate was the same order of 
magnitude as recorded in other studies where people were 
treated concomitantly with sulfonylureas and basal insulin 
[45, 65, 82]. Clinicians should always consider stopping 
sulfonylurea therapy when combining with insulin, par-
ticularly when treatment with IDegLira is initiated.
Key clinical learning Most OADs can be continued 
when initiating IDegLira without modification; however, 
we recommend the discontinuation of DPP-4 inhibitors 
and a reduction in the dose of sulfonylureas, as well as a 
plan for discontinuation, when initiating IDegLira. Peo-
ple receiving pioglitazone treatment should be closely 
monitored for edema and heart failure when initiating 
IDegLira.
8.1.2  Switching from GLP‑1RA or Basal Insulin to IDegLira
Prior basal insulin or GLP-1RA therapy should be dis-
continued prior to the initiation of IDegLira. The recom-
mended starting dose of IDegLira in this group of people 
is 16 units/dose steps (16 units degludec and 0.6 mg lira-
glutide) [7, 66]. Although 16 units/dose steps of IDegLira 
is likely to be a decrease in the total daily insulin dose 
in people transferring from basal insulin, because of the 
complementary actions of the two components, glycemic 
control can be achieved at a lower insulin dose [8]. Fur-
thermore, it is simple to titrate the dose of IDegLira, if 
necessary.
A post hoc analysis of the DUAL V trial investigated 
participant outcomes by pretrial insulin dose (20 to < 30, 
30 to < 40 and 40 to ≤ 50 units/day) and demonstrated 
that, regardless of pretrial dose, participants treated with 
IDegLira achieved a significantly greater reduction in 
 HbA1c from baseline to EOT, compared with IGlar U100 
[83]. There was also no clinically significant increase in 
self-measured blood glucose (SMBG) in any pretrial dose 
group when switching to IDegLira, and no withdrawals 
due to hyperglycemia with IDegLira in the first 8 weeks 
following the switch [83]. Furthermore, results from a 
real-world population of people with T2D (92% of whom 
were being treated with insulin) demonstrated that switch-
ing to IDegLira resulted in improved glucose control and 
body weight loss [84]. The data from both clinical trials 
and real-world studies therefore suggest that IDegLira 
can be an effective and often superior substitution for 
any basal insulin dose [83, 84]. Additionally, results from 
DUAL VII demonstrate that in people whose diabetes was 
not controlled with basal insulin, IDegLira provides com-
parable  HbA1c reductions as basal–bolus insulin, with sig-
nificantly lower hypoglycemia rates and weight loss com-
pared with weight gain [40]. People requiring basal–bolus 
insulin can represent a challenging patient population, 
as initiation and intensification of basal–bolus insulin 
can have limited success in terms of achieving  HbA1C 
targets, and is often associated with increased rates of 
hypoglycaemia and increased weight. Furthermore, treat-
ment with IDegLira provides a simple, less burdensome 
injectable therapy compared with basal–bolus insulin, and 
this may help with taking medication [85].
HCPs may be concerned that IDegLira has a maxi-
mum dose of 50 units/dose steps [7, 66], compared with 
no maximum doses for IGlar U100 and degludec. How-
ever, data from the DUAL studies demonstrate that the 
majority of participants (≥ 60%) treated with IDegLira 
achieved the  HbA1c target of < 7.0% (< 53 mmol/mol) 
at ≤ 50 units/dose steps. Additionally, the EXTRA real-
world chart review of people with T2D found that only 
67 (12%) people reached or exceeded the maximum dose 
160 S. Harris et al.
(50 units/dose steps) of IDegLira either at initiation or at 
6 months of follow-up [68].
Key clinical learning People with T2D switching from 
GLP-1RAs or basal insulin to IDegLira will need to dis-
continue their prior therapy and initiate IDegLira at 16 
units/dose steps. Studies have shown that although this 
might require a temporary reduction in dose, there was 
no long-term loss of glycemic control.
8.1.3  Initiation of IDegLira in People with CV Risk
There are currently no guidelines that specifically recom-
mend IDegLira in the treatment of people with T2D and 
CV risk.
The results of several early CVOTs showed that lowering 
 HbA1c has a major beneficial impact on reducing micro-
vascular complications in diabetes, but no clear benefit was 
seen on macrovascular disease [86–91]. Despite longer-term 
studies establishing a positive legacy effect of tight glycemic 
control on CV outcomes [15, 92], an increase in CV mortal-
ity was reported in high-risk individuals (those with addi-
tional CV risk factors) assigned to intensive glucose control 
in the ACCORD trial [90, 93]. Thus, guidelines recommend 
that targets are individualized to the needs of each person 
with diabetes and his or her disease factors [19].
The most recent American Diabetes Association (ADA)/
European Association for the Study of Diabetes consensus 
statement recommends GLP-1RA treatment, particularly 
liraglutide, as an early step for the intensification of therapy 
in T2D in people with established atherosclerotic CV disease 
[3]. It should be noted that this recommendation is based 
on evidence from the LEADER CVOT, which examined 
the CV effect of once-daily liraglutide 1.8 mg [70]; thus, 
it is not yet known if lower doses of liraglutide provide the 
same CV benefits. If individuals with T2D still do not reach 
their glycemic targets, the consensus ADA statement rec-
ommends further intensification, with the initiation of basal 
insulin therapy with either degludec or IGlar U100 listed as 
potential options, as a result of their documented CV safety 
profiles [3].
8.2  Titration
The need for titration is a potential cause of therapeutic iner-
tia and thus a barrier to achievement of good glycemic con-
trol. It is important that IDegLira is titrated to a therapeutic 
dose, but fortunately the titration method is quite simple and 
does not require carbohydrate counting. It is recommended 
in the product label that the dose of IDegLira is adjusted 
twice weekly, in increments of 2 units/dose steps, based on 
three consecutive FPG readings (Fig. 3) [7, 66]. However, 
the DUAL VI trial found that once-weekly titration of IDe-
gLira was non-inferior in terms of glycemic control [64], 
thus offering clinicians and people with diabetes different 
titration options.
Titration of IDegLira was critical to achieving the gly-
cemic control observed in the DUAL trials. Participants 
initiated IDegLira at a low dose (10 or 16 units/dose steps, 
depending on prior therapy [7, 66]), but reached approxi-
mately 40 units/dose steps over the 26- or 32-week trials, and 
this dose was required to achieve the reported reductions in 
 HbA1c. Real-world data from the EXTRA study demonstrated 
that IDegLira titration in clinical practice is not as aggressive 
as in the clinical trials, with people with T2D reaching an 
average dose of 30 units/dose steps after 6 months of treat-
ment, despite starting at a higher dose at initiation, achieving 
a mean  HbA1c of 7.5% (59 mmol/mol) [68].
The initiation of IDegLira at a low dose, followed by 
titration, reduces the incidence of GI adverse events usu-
ally observed with GLP-1RAs. GI adverse events were a 
common cause of discontinuation for liraglutide therapy 
in DUAL I, whereas participants treated with IDegLira 
were less likely to discontinue as a result of adverse 
events (5.8% compared with 1.2%, respectively) [8]. As 
a result of the need to initiate IDegLira at a low dose, it 
can take several weeks for individuals with T2D to reach 
Fig. 3  Twice-weekly dose titra-
tion recommendations for IDe-
gLira. aFPG measurement must 
be from the proceeding 3 days. 
FPG fasting plasma glucose, 
IDegLira insulin degludec/
liraglutide
Step 1: Calculate your average FPG measurement
FPG measurement 1 + FPG measurement 2 + FPG measurement 3a = Average FPG
3
Step 2: Compare your average FPG with the table below, and adjust IDegLira dose as shown
Fasting self-measured plasma glucose
mmol/L mg/dL
 yb esaerceD ↓27<0.4< 2 units/dose steps
esod niatniaM09–270.5–0.4
 yb esaercnI ↑09>0.5> 2 units/dose steps
Dose adjustment
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their  HbA1c targets. The DUAL trials demonstrated that 
people with T2D can reach their  HbA1c target of < 7.0% 
(< 53 mmol/mol) at approximately 8–16 weeks [8, 40, 41, 
61–65], at a dose of approximately 40 units/dose steps.
In people with diabetic retinopathy and poor long-term gly-
cemic control, intensification of therapy with insulin has been 
associated with the worsening of their condition [94]. This risk 
appears to be associated with rapid reduction of blood glucose 
levels. Therefore, we think that HCPs should consider less 
aggressive titration of IDegLira in these people as this may 
avoid their condition worsening unnecessarily.
Key clinical learning It is important to monitor FPG lev-
els and adjust the dose of IDegLira, in increments of 2 units/
dose steps, to achieve the levels of glycemic control seen in 
the DUAL trials. However, less aggressive titration may be 
required in people with diabetic retinopathy and poor long-
term glycemic control.
9  Conclusions
Therapeutic inertia is a real and ongoing challenge, particu-
larly when initiating and intensifying insulin therapies in 
people who would benefit from an  HbA1c goal of < 7.0% 
(53 mmol/mol). This inertia may in part be due to concerns 
of people with T2D and HCPs around hypoglycemia, body 
weight gain, and treatment and titration complexity. Combi-
nation therapies, such as IDegLira, offer the opportunity to 
improve efficacy with better outcomes for body weight and 
hypoglycemia compared with other insulin-based regimens.
Current guidance recommends the initiation of injectable 
combinations either as the first injectable in people with 
 HbA1c > 10.0% (> 86 mmol/mol) and/or 2.0% (22 mmol/
mol) above target, or if people with T2D are not reaching 
 HbA1c targets on monotherapy. The DUAL clinical trial 
program demonstrated the efficacy and safety of IDeg-
Lira not only compared with GLP-1RA monotherapy but 
also compared with basal insulin and basal–bolus therapy 
regardless of prior insulin therapy. In a real-world setting, 
the EXTRA study also found that people treated with IDe-
gLira for 6 months experienced improvements in clinical 
endpoints compared with the beginning of the study. While 
there was a lower reduction in  HbA1c than recorded in the 
DUAL program, this may be due to the treatment regimen 
not being followed as rigorously in a real-world setting, as 
has been demonstrated previously [95].
We recommend that FRCs, such as IDegLira, are con-
sidered as a first injectable therapy for people with T2D, 
and as a superior alternative to the traditional basal–bolus 
approach for optimizing glycemic control in individuals 
not reaching their targets on basal insulin. IDegLira should 
be initiated at 10 units/dose steps unless the individual is 
already taking insulin, in which case 16 units/dose steps is 
recommended. The dose should then be titrated by 2 units/
dose steps twice weekly until the individual reaches his or 
her glycemic target.
Overall, the benefits of consistently improved glycemic 
control, fewer GI adverse events (than GLP-1RA monother-
apy), a lower incidence of hypoglycemia and body weight 
loss or neutrality (compared with body weight gain seen 
with insulin), combined with a simple treatment regimen 
and a durable effect, indicate that IDegLira may help over-
come therapeutic inertia and improve medication adherence 
in people with T2D, thereby leading to better long-term dia-
betes control. The evidence suggests that IDegLira may pro-
vide a more suitable treatment option than insulin alone for 
individuals at increased risk of hypoglycemia, or concerned 
about the body weight gain associated with an insulin (basal 
or basal–bolus) regimen.
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